Cited by 610Lung Cancer Treatments and MutationsLung Cancer Diagnosis and TreatmentLung Cancer Research Studies

The DOI matches its Crossref record; 32 of the 33 references it cites were found in a registry or an index.

Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial

Open access

Paz-Ares, Luis, de Marinis, Filippo, Dediu, Mircea, Thomas, Michael, Pujol, Jean-Louis, Bidoli, Paolo, Molinier, Olivier, Sahoo, Tarini Prasad, Laack, Eckart, Reck, Martin, Corral, Jesús, Melemed, Symantha, John, William, Chouaki, Nadia, Zimmermann, Annamaria H, Visseren-Grul, Carla, Gridelli, Cesare·2012·The Lancet Oncology

DOI 10.1016/s1470-2045(12)70063-3

Open this paper in CoChat — free account

Abstract

Background Patients with advanced non-squamous non-small-cell lung cancer (NSCLC) benefit from pemetrexed maintenance therapy after induction therapy with a platinum-containing, non-pemetrexed doublet. The PARAMOUNT trial investigated whether continuation maintenance with pemetrexed improved progression-free survival after induction therapy with pemetrexed plus cisplatin.Methods In this double-blind, multicentre, phase 3, randomised placebo-controlled trial, patients with advanced non-squamous NSCLC aged 18 years or older, with no previous systemic chemotherapy for lung cancer, with at least one measurable lesion, and an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 participated. Before randomisation, patients entered an induction phase which consisted of four cycles of induction pemetrexed (500 mg/m(2)) plus cisplatin (75 mg/m(2)) on day 1 of a 21-day cycle. Patients who did not progress after completion of four cycles of induction and who had an ECOG performance status of 0 or 1 were stratified according to disease stage (IIIB or IV), ECOG performance status (0 or 1), and induction response (complete or partial response, or stable disease), and randomly assigned (2:1 ratio) to receive maintenance therapy with either pemetrexed (500 mg/m(2) every 21 days) plus best supportive care or placebo plus best supportive care until disease progression. Randomisation was done with the Pocock and Simon minimisation method. Patients and investigators were masked to treatment assignment. The primary endpoint was progression-free survival in the intention-to-treat population. This study is registered with ClinicalTrials.gov, NCT00789373.Findings Of the 1022 patients enrolled, 939 participated in the induction phase. Of these, 539 patients were randomly assigned to receive continuation maintenance with pemetrexed plus best supportive care (n=359) or with placebo plus best supportive care (n=180). Among the 359 patients randomised to continuation maintenance with pemetrexed, there was a significant reduction in the risk of disease progression over the placebo group (HR 0·62, 95% CI 0·49-0·79; p<0·0001). The median progression-free survival, measured from randomisation, was 4·1 months (95% CI 3·2-4·6) for pemetrexed and 2·8 months (2·6-3·1) for placebo. Possibly treatment-related laboratory grade 3-4 adverse events were more common in the pemetrexed group (33 [9%] of 359 patients) than in the placebo group (one [<1%] of 180 patients; p<0·0001), as were non-laboratory grade 3-5 adverse events (32 [9%] of 359 patients in the pemetrexed group; eight [4%] of 180 patients in the placebo group; p=0·080); one possibly treatment-related death was reported in each group. The most common adverse events of grade 3-4 in the pemetrexed group were anaemia (16 [4%] of 359 patients), neutropenia (13 [4%]), and fatigue (15 [4%]). In the placebo group, these adverse events were less common: anaemia (one [<1%] of 180 patients), neutropenia (none), and fatigue (one <1%]). The most frequent serious adverse events were anaemia (eight [2%] of 359 patients in the pemetrexed group vs none in the placebo group) and febrile neutropenia (five [1%] vs none). Discontinuations due to drug-related adverse events occurred in 19 (5%) patients in the pemetrexed group and six (3%) patients in the placebo group.Interpretation Continuation maintenance with pemetrexed is an effective and well tolerated treatment option for patients with advanced non-squamous NSCLC with good performance status who have not progressed after induction therapy with pemetrexed plus cisplatin.Funding Eli Lilly and Company.

Integrity signals

Registry

Crossref · 10.1016/s1470-2045(12)70063-3

Cites

32 of 32 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1992) · Springer series in statistics · doi:10.1007/978-1-4612-4380-9_25 · Cited by 45,239
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
AJCC Cancer Staging Manual
(2016) · Springer eBooks · doi:10.1007/978-3-319-40618-3 · Cited by 17,300
EuroQol: a new facility for the measurement of health-related quality of life
(1990) · Health Policy · doi:10.1016/0168-8510(90)90421-9 · Cited by 15,736
New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660
Toxicity and response criteria of the Eastern Cooperative Oncology Group
Oken, M. M., Creech, R. H., Tormey, D. C., Horton, J., Davis, T. E., Mcfadden, E. T., & Carbone, P. P. (1982) · American Journal of Clinical Oncology · doi:10.1097/00000421-198212000-00014 · Cited by 11,686
Paclitaxel–Carboplatin Alone or with Bevacizumab for Non–Small-Cell Lung Cancer
Sandler, A., Gray, R., Perry, M. C., Brahmer, J., Schiller, J. H., Dowlati, A., Lilenbaum, R., & Johnson, D. H. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa061884 · Cited by 5,761
Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non–Small-Cell Lung Cancer
Scagliotti, G. V., Parikh, P., von Pawel, J., Biesma, B., Vansteenkiste, J., Manegold, C., Serwatowski, P., Gatzemeier, U., Digumarti, R., Zukin, M., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.0375 · Cited by 3,203
Analysis of Binary Data
Cox, D. R. (2008) · Springer eBooks · doi:10.1007/978-0-387-32833-1_5 · Cited by 2,687
Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Novello, S., Barlesi, F., Califano, R., Cufer, T., Ekman, S., Levra, M. G., Kerr, K., Popat, S., Reck, M., Senan, S., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw326 · Cited by 2,631
Self-citation

Show all 33 references

Research works printed but not linked: 1

Ciuleanu, 2008, Impact of induction chemotherapy on the outcome of treatment with pemetrexed in patients with advanced non-small-cell lung cancer: a retrospective analysis of a phase III trial, Ann Oncol, 19, viii98

Sorted by citations

Items 301–400 of 607

The efficacy and toxicity of maintenance therapy with bevacizumab plus pemetrexed versus bevacizumab/pemetrexed alone for stage IIIB/IV nonsquamous non‐small cell lung cancer: A meta‐analysis of randomized controlled trials
Liu, M., Luo, N., Fang, Z., Liu, Q., Yi, F., Wei, Y., Zhang, X., & Zhang, W. (2021) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/jcpt.13534 · Cited by 9
Activity of pemetrexed-based regimen as first-line chemotherapy for advanced non-small cell lung cancer with asymptomatic inoperable brain metastasis: a retrospective study
Zhu, W., Røe, O. D., Wu, C., Li, W., Guo, R., Gu, Y., Liu, Y., Shu, Y., & Chen, X. (2015) · Journal of Chemotherapy · doi:10.1179/1973947815y.0000000005 · Cited by 9
Bevacizumab-containing chemotherapy for non-small cell lung cancer patients: a population-based observational study by the Ibaraki thoracic integrative (POSITIVE) research group
Nakamura, H., Satoh, H., Kaburagi, T., Nishimura, Y., Shinohara, Y., Inagaki, M., Endo, T., Saito, T., Hayashihara, K., Hizawa, N., et al. (2012) · Medical Oncology · doi:10.1007/s12032-012-0318-5 · Cited by 9
Feasibility trial for adjuvant chemotherapy with docetaxel plus cisplatin followed by single agent long-term administration of S-1 chemotherapy in patients with completely resected non-small cell lung cancer: Thoracic Oncology Research Group Study 0809
Niho, S., Ikeda, N., Michimae, H., Suzuki, K., Sakai, H., Kaburagi, T., Minato, K., Kato, T., Okamoto, H., Seto, T., et al. (2013) · British Journal of Cancer · doi:10.1038/bjc.2013.378 · Cited by 9
Clinical effect of pemetrexed as the first‐line treatment in Chinese patients with advanced anaplastic lymphoma kinase‐positive non‐small cell lung cancer
Ma, D., Hao, X., Wang, Y., Xing, P., & Li, J. (2016) · Thoracic Cancer · doi:10.1111/1759-7714.12353 · Cited by 9
Doublet chemotherapy with cisplatin and pemetrexed is associated with a favorable outcome in patients with advanced non-squamous non-small-cell lung cancer who are eligible for bevacizumab and maintenance therapy
Nakashima, K., Murakami, H., Omori, S., Wakuda, K., Ono, A., Kenmotsu, H., Naito, T., Endo, M., & Takahashi, T. (2016) · Molecular and Clinical Oncology · doi:10.3892/mco.2016.1001 · Cited by 9
First-in-class multifunctional TYMS nonclassical antifolate inhibitor with potent in vivo activity that prolongs survival
Guijarro, M. V., Kellish, P. C., Dib, P., Paciaroni, N. G., Nawab, A., Andring, J. T., Kulemina, L. V., Borrero, N. V., Modenutti, C. P., Feely, M., et al. (2023) · JCI Insight · doi:10.1172/jci.insight.158798 · Cited by 8
Osimertinib in the treatment of resected EGFR-mutated non-small cell lung cancer: a cost-effectiveness analysis in the United States
Huo, G., Song, Y., Liu, W., Cao, X., & Chen, P. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1300183 · Cited by 8
Spartalizumab in combination with platinum-doublet chemotherapy with or without canakinumab in patients with PD-L1-unselected, metastatic NSCLC
Santoro, A., Pilar, G., Tan, D. S.-W., Zugazagoitia, J., Shepherd, F. A., Bearz, A., Barlési, F., Kim, T. M., Overbeck, T. R., Felip, E., et al. (2024) · BMC Cancer · doi:10.1186/s12885-024-12841-2 · Cited by 6
Sequential treatment of icotinib after first-line pemetrexed in advanced lung adenocarcinoma with unknown EGFR gene status.
Zheng, Y., Fang, W. J., Deng, J., Zhao, P., Xu, N., & Zhou, J. (2014) · PubMed Central · doi:10.3978/j.issn.2072-1439.2014.07.18 · Cited by 8
The efficacy and safety of pemetrexed plus bevacizumab in previously treated patients with advanced non-squamous non-small cell lung cancer (ns-NSCLC)
Ding, L., Liu, K., Jiang, Z., Chen, Q., Zhou, N., Liang, Y., Gao, H., Hong, X., & Wu, H. (2014) · Tumor Biology · doi:10.1007/s13277-014-2862-4 · Cited by 8
QoL analyses from INFORM study, a phase III study of gefitinib versus placebo as maintenance therapy in advanced NSCLC
Yang, Y.-P., Ma, Y., Huang, Y., Zhao, Y., Fang, W., Hong, S.-D., Tian, Y., Xue, C., Sheng, J., & Zhang, L. (2015) · Scientific Reports · doi:10.1038/srep11934 · Cited by 8
Standard of care in immunotherapy trials: Challenges and considerations
Rivalland, G., Scott, A. M., & John, T. (2017) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2016.1277845 · Cited by 8
Impact of Maintenance Therapy for Patients with Non-small Cell Lung Cancer in a Real-world Setting
Yoh, K., Goto, Y., Naito, Y., Kishi, K., Mori, K., Hotta, K., Hosomi, Y., Yamada, K., Tanai, C., Tomizawa, Y., et al. (2017) · Anticancer Research · doi:10.21873/anticanres.11478 · Cited by 8
Efficacy of Pemetrexed-based Chemotherapy in Comparison to Non-Pemetrexed-based Chemotherapy in Advanced, ALK+ Non-Small Cell Lung Cancer
Jo, J., Kim, S. H., Kim, Y. J., Lee, J. H., Kim, M., Keam, B., Kim, T. M., Kim, D., Heo, D. S., Chung, J.-H., et al. (2018) · Yonsei Medical Journal · doi:10.3349/ymj.2018.59.2.202 · Cited by 8
Randomized phase II study of pemetrexed-cisplatin or docetaxel-cisplatin plus thoracic intensity-modulated radiation therapy in patients with stage IV lung adenocarcinoma.
Su, S., Li, M., Geng, Y., Yang, W., Ma, Z., Li, Q., Hu, Y., Yang, W.-W. O., Liu, L., & Lü, B. (2019) · PubMed Central · Cited by 8
LKB1 mutations are not associated with the efficacy of first-line and second-line chemotherapy in patients with advanced non-small-cell lung cancer (NSCLC): a post hoc analysis of the TAILOR trial
Vernieri, C., Ganzinelli, M., Rulli, E., Farina, G., Bettini, A., Bareggi, C., Rosso, L., Signorelli, D., Galli, G., Russo, G. L., et al. (2020) · ESMO Open · doi:10.1136/esmoopen-2020-000748 · Cited by 8
Better survival in impaired renal function patients with metastatic non-small cell lung cancer treated by cisplatin-pemetrexed
Magali, L., Pascal, F., Aho, S., Boulin, M., Zouak, A., Tinel, C., & Mousson, C. (2020) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-020-02935-8 · Cited by 8
Pemetrexed maintenance with or without pembrolizumab in non-squamous non-small cell lung cancer: A cross-trial comparison of KEYNOTE-189 versus PARAMOUNT, PRONOUNCE, and JVBL
Garon, E. B., Kim, J. S., & Govindan, R. (2020) · Lung Cancer · doi:10.1016/j.lungcan.2020.11.018 · Cited by 8
Docetaxel maintenance therapy versus best supportive care after first-line chemotherapy with different dose docetaxel plus cisplatin for advanced non-small cell lung cancer (TFINE study, CTONG-0904): an open-label, randomized, phase III trial
Zhang, L., Lü, S., Cheng, Y., Hu, Z., Wu, Y.-L. L. C., Chen, Z., Chen, G., Liu, X., Yang, J., Zhang, L., et al. (2021) · Annals of Translational Medicine · doi:10.21037/atm-20-8078 · Cited by 8
Adding Base-Excision Repair Inhibitor TRC102 to Standard Pemetrexed–Platinum–Radiation in Patients with Advanced Nonsquamous Non–Small Cell Lung Cancer: Results of a Phase I Trial
Biswas, T., Dowlati, A., Kunos, C. A., Pink, J. J., Oleinick, N. L., Malik, S., Fu, P., Cao, S., Bruno, D. S., Bajor, D. L., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-2025 · Cited by 8
The Pharmacoeconomic Benefits of Pemetrexed Dose Individualization in Patients With Lung Cancer
de Rouw, N., de Boer, M., Boosman, R. J., van den Heuvel, M. M., Burger, D. M., Lieverse, J. E., Derijks, H. J., Frederix, G., & ter Heine, R. (2022) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.2529 · Cited by 8
Superiority of Concomitant Chemoradiation Over Sequential Chemoradiation in Inoperable, Locally Advanced Non–Small Cell Lung Cancer: Challenges in the Selection of Appropriate Chemotherapy
Bi, N., & Wang, L. (2014) · Seminars in Radiation Oncology · doi:10.1016/j.semradonc.2014.11.003 · Cited by 8
Continuation maintenance therapy with S-1 in chemotherapy-naïve patients with advanced squamous cell lung cancer
Suzuki, S., Karayama, M., Inui, N., Fujisawa, T., Enomoto, N., Nakamura, Y., Kuroishi, S., Matsuda, H., Yokomura, K., Koshimizu, N., et al. (2016) · Investigational New Drugs · doi:10.1007/s10637-016-0365-4 · Cited by 8
Multicentric retrospective analysis of platinum‐pemetrexed regimens as first‐line therapy in non‐squamous non‐small cell lung cancer patients: A “snapshot” from clinical practice
Cortellini, A., Gambale, E., Cannita, K., Brocco, D., Parisi, A., Napoleoni, L., Masedu, F., Irtelli, L., Tursi, M. D., Natoli, C., et al. (2017) · Thoracic Cancer · doi:10.1111/1759-7714.12570 · Cited by 8
Evaluation of changes in renal function in PARAMOUNT: a phase III study of maintenance pemetrexed plus best supportive care versus placebo plus best supportive care after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer
Middleton, G., Gridelli, C., de Marinis, F., Pujol, J.-L., Reck, M., Ramlau, R., Parente, B., Pieters, T., Visseren‐Grul, C., Antonio, B. S., et al. (2018) · Current Medical Research and Opinion · doi:10.1080/03007995.2018.1439462 · Cited by 8
Self-citation
A phase I study of the vascular endothelial growth factor inhibitor Vatalanib in combination with Pemetrexed disodium in patients with advanced solid tumors
Wang, F., Molina, J. R., Satele, D., Yin, J., Lim, V.-S., & Adjei, A. A. (2018) · Investigational New Drugs · doi:10.1007/s10637-018-0690-x · Cited by 8
Utility and safety of maintenance chemotherapy in advanced non–small cell lung cancer across various performance status categories: real-world experience
Prasad, K. T., Muthu, V., Biswas, B., Malik, P. S., Dabkara, D., Ganguly, S., Ghosh, J., Kataria, B., Khurana, S., Verma, S., et al. (2020) · Current Problems in Cancer · doi:10.1016/j.currproblcancer.2020.100565 · Cited by 8
First-line versus second-line use of pralsetinib in treatment of rearranged during transfection (RET) fusion-positive advanced non-small cell lung cancer: a cost-effectiveness analysis
Liu, W., Huo, G., Li, M., & Chen, P. (2023) · Translational Lung Cancer Research · doi:10.21037/tlcr-23-469 · Cited by 7
The role of thymidylate synthase in non-small cell lung cancer treated with pemetrexed continuation maintenance therapy
Yang, M., Fan, W., Pu, X., Meng, L., & Wang, J. (2016) · Journal of Chemotherapy · doi:10.1080/1120009x.2016.1254940 · Cited by 7
An Open-Label Randomized Controlled Trial Comparing the Efficacy and Safety of Pemetrexed-Carboplatin versus (Weekly) Paclitaxel-Carboplatin as First-Line Chemotherapy in Advanced Non-Squamous Non-Small Cell Lung Cancer
Yadav, A. K., Malik, P. S., Khurana, S., Jain, D., Vishnubhatla, S., Yadav, M., Pathy, S., Mohan, A., & Kumar, L. (2021) · Oncology · doi:10.1159/000514577 · Cited by 7
Bevacizumab plus platinum-based chemotherapy in advanced non-squamous non-small-cell lung cancer: a randomized, open- label phase 2 study (CLEAR)
Udagawa, H., Sugiyama, E., Harada, T., Atagi, S., Koyama, R., Watanabe, S., Nakamura, Y., Harada, D., Hataji, O., Tanaka, F., et al. (2021) · Translational Lung Cancer Research · doi:10.21037/tlcr-21-240 · Cited by 7
Oral vinorelbine plus cisplatin followed by maintenance oral vinorelbine as first-line treatment for advanced non-small cell lung cancer
Farhat, F. S., Ghosn, M. G., & Kattan, J. G. (2015) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-015-2785-9 · Cited by 7
A Prediction Model for Chemotherapy-Induced Thrombocytopenia Based on Real-World Data and a Close Relationship Between AST/ALT Ratio and Platelet Count in Patients with Solid Tumors
Song, B., Zhou, S., Li, C., Zheng, H., Zhang, X., Jin, X., Fu, J., & Hu, H. (2022) · International Journal of General Medicine · doi:10.2147/ijgm.s383349 · Cited by 7
In Silico Evaluation of HN-N07 Small Molecule as an Inhibitor of Angiogenesis and Lymphangiogenesis Oncogenic Signatures in Non-Small Cell Lung Cancer
Chen, L.-C., Mokgautsi, N., Kuo, Y., Wu, A. T. H., & Huang, H. (2023) · Biomedicines · doi:10.3390/biomedicines11072011 · Cited by 7
Pemetrexed plus platinum versus pemetrexed alone in non-small cell lung cancer patients who have progressed after first-line EGFR TKIs
Lee, S. J., Sun, J., Lee, S., Ahn, J. S., Park, K., & Ahn, M. (2015) · Lung Cancer · doi:10.1016/j.lungcan.2015.08.020 · Cited by 7
Evaluation of a novel rash scale and a serum proteomic predictor in a randomized phase II trial of sequential or concurrent cetuximab and pemetrexed in previously treated non-small cell lung cancer
Maitland, M. L., Levine, M. R., Lacouture, M. E., Wroblewski, K., Chung, C. H., Gordon, I. O., Szeto, L. L., Ratko, G., Soltani, K., Kozloff, M. F., et al. (2014) · BMC Cancer · doi:10.1186/1471-2407-14-5 · Cited by 7
Advanced Non-Small Cell Lung Cancer (NSCLC): Maintenance Therapy for All?
Sadraei, N. H., & Pennell, N. A. (2012) · Current Treatment Options in Oncology · doi:10.1007/s11864-012-0209-1 · Cited by 7
Reduced folate carrier (RFC) as a predictive marker for response to pemetrexed in advanced non-small cell lung cancer (NSCLC)
Álvarez-Fernández, C., Perez, Q., Ruiz-Echeverria, L., Rubí, D. R., Sánchez‐Lorenzo, L., Torres, W. L., Izquierdo-Manuel, M., Berros, J. P., Luque-Cabal, M., Jiménez‐Fonseca, P., et al. (2013) · Investigational New Drugs · doi:10.1007/s10637-013-9992-1 · Cited by 7
Efficacy of pemetrexed-based regimen in relapsed advanced thymic epithelial tumors and its association with thymidylate synthase level
Song, Z., & Qian, X. (2016) · OncoTargets and Therapy · doi:10.2147/ott.s105949 · Cited by 7
Long time response with chemotherapy in ROS1 NSCLC patient with unusual metastatic site
Franchina, T., Russo, A., Ricciardi, G. R. R., Liguori, G., Herberg, A., Normanno, N., & Adamo, V. (2016) · Cancer Biology & Therapy · doi:10.1080/15384047.2016.1219822 · Cited by 7
AURA 3: the last word on chemotherapy as a control arm in EGFR mutant NSCLC?
Ng, T. L., & Camidge, D. R. (2017) · Annals of Translational Medicine · doi:10.21037/atm.2017.03.73 · Cited by 7
Predictive factors for long‐term responders of pemetrexed maintenance treatment in non‐small cell lung cancer
Yoon, J., Park, C., Choi, Y. D., Oh, I., & Kim, Y. (2019) · Thoracic Cancer · doi:10.1111/1759-7714.13033 · Cited by 7
Outcome of maintenance systemic chemotherapy with drug-free interval for metastatic urothelial carcinoma
Abe, T., Minami, K., Harabayashi, T., Sazawa, A., Chiba, H., Kikuchi, H., Miyata, H., Matsumoto, R., Osawa, T., Maruyama, S., et al. (2019) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyz084 · Cited by 7
Treatment paradigms in advanced non-small-cell lung cancer.
McCoach, C. E., & Kelly, K. L. (2013) · PubMed · Cited by 7
The Role of Combination Maintenance with Pemetrexed and Bevacizumab for Advanced Stage Nonsquamous Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis
Shan, F., Zhang, B., Sun, L., Xie, L., Shen, M., & Ruan, S. (2018) · BioMed Research International · doi:10.1155/2018/5839081 · Cited by 7
First-line pemetrexed-platinum doublet chemotherapy with or without bevacizumab in non-squamous non-small cell lung cancer: A real-world propensity score-matched study in China
Qi, F., Hu, X., Liu, Y., Wang, Z., Duan, J., Wang, J., & Dong, M. (2019) · Chinese Journal of Cancer Research · doi:10.21147/j.issn.1000-9604.2019.05.05 · Cited by 7
Outcomes for Pembrolizumab Stratified by Pemetrexed Maintenance Post Pembrolizumab–Platinum–Pemetrexed Induction in Metastatic Non-Small-Cell Lung Cancer
Goldschmidt, J. H., Annavarapu, S., Venkatasetty, D., Wang, Y., Santorelli, M. L., Burke, T. W., & Pennell, N. A. (2024) · Immunotherapy · doi:10.2217/imt-2023-0313 · Cited by 6
ROS1-rearranged non-small cell lung cancer: Understanding biology and optimizing management in the era of new approvals
Myall, N. J., & Das, M. S. (2024) · Current Problems in Cancer · doi:10.1016/j.currproblcancer.2024.101133 · Cited by 6
Retreatment with pemetrexed chemotherapy in advanced non-small cell lung cancer patient.
Song, Z., & Zhang, Y. (2014) · PubMed Central · doi:10.3978/j.issn.2072-1439.2014.06.15 · Cited by 6
Phase II trial of pemetrexed continuation--maintenance after carboplatin-based induction in untreated non-squamous non-small cell lung cancer.
Minami, S., Kijima, T., Komuta, K., Kumagai, T., Imamura, F., Yokota, S., Takeuchi, Y., Nakatani, T., Tachibana, I., & Kawase, I. (2013) · PubMed · Cited by 6
First-Line Therapeutic Options for Advanced Non-Small-Cell Lung Cancer in the Molecular Medicine Era
Capelletto, E., Novello, S., & Scagliotti, G. V. (2014) · Future Oncology · doi:10.2217/fon.13.247 · Cited by 6
The Challenging Management of Cancer: An Immunonephrologist’s Perspective
Fenoglio, R., Roccatello, D., Simone, E. D., Vecchio, G. D., Ferro, M., Quattrocchio, G., Barreca, A., & Sciascia, S. (2020) · Kidney & Blood Pressure Research · doi:10.1159/000511256 · Cited by 6
Molecular genetic tests in survival factors in patients with NSCLC in the clinical practice of Kazakhstan
Yessentayeva, S., Makarov, V. A., Kalmatayeva, Z., Zhakenova, Z., & Арыбжанов, Д. Т. (2021) · Medical Journal of the Islamic Republic of Iran · doi:10.47176/mjiri.35.133 · Cited by 6
Overall Survival and Safety With Pemetrexed/Platinum ± Anti-VEGF Followed by Pemetrexed ± Anti-VEGF Maintenance in Advanced Nonsquamous Non–Small-Cell Lung Cancer: A Pooled Analysis of 4 Randomized Studies
Garon, E. B., Peterson, P. M., Rizzo, M. T., & Kim, J. S. (2021) · Clinical Lung Cancer · doi:10.1016/j.cllc.2021.10.010 · Cited by 6
Outcomes of Anlotinib Maintenance Therapy in Patients With Advanced NSCLC in a Real-World Setting
Li, J., Han, B., & Liu, H. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.785865 · Cited by 6
Selection of chemotherapy for non-small cell lung cancer is facilitated by new therapeutic strategies.
Wang, Z. (2014) · Europe PMC (PubMed Central) · Cited by 6
Similar survival benefits of a good response and stable disease to platinum-based chemotherapy in non-small cell lung cancer
Tamura, T., Kurishima, K., Nakazawa, K., Ishikawa, H., Satoh, H., & Hizawa, N. (2015) · Oncology Letters · doi:10.3892/ol.2015.3350 · Cited by 6
Maintenance treatment with chemotherapy and immunotherapy in non-small cell lung cancer: a case report
Llanos, A., Savignano, M., & Cinat, G. (2012) · Frontiers in Oncology · doi:10.3389/fonc.2012.00152 · Cited by 6
Full-dose pemetrexed plus cisplatin combined with concurrent thoracic radiotherapy for previously untreated advanced nonsquamous non-small cell lung cancer
Zhang, Q., Cai, X., Zhu, Z.-F., Yu, W. J., Liu, Q., Feng, W., Mengchen, X., & Fu, X. (2015) · Anti-Cancer Drugs · doi:10.1097/cad.0000000000000215 · Cited by 6
Continuous pemetrexed treatment for brain metastasis in non-small cell lung cancer—A report of two cases
Ochi, N., Yamane, H., Yamagishi, T., & Takigawa, N. (2012) · Lung Cancer · doi:10.1016/j.lungcan.2012.12.010 · Cited by 6
Safety and efficacy of pemetrexed in gynecologic cancers: A systematic literature review
Miller, D. S., Tai, D. F., Obasaju, C. K., & Vergote, I. B. (2013) · Modern Chemotherapy · doi:10.4236/mc.2013.22004 · Cited by 6
Improved Survival of Advanced Lung Cancer in Singapore Over the Past Decade
Toh, C., Ong, W. S., Tan, D. S. W., Ng, Q. S., Kanesvaran, R., Fong, K. W., Ang, M., Tan, E. H., & Lim, W. T. (2017) · Annals of the Academy of Medicine Singapore · doi:10.47102/annals-acadmedsg.v46n9p333 · Cited by 6
Indian consensus statement for treatment of advanced non small cell lung cancer: First line, maintenance, and second line
Indian Cooperative Oncology Network (ICON) (2017) · Indian Journal of Cancer · doi:10.4103/ijc.ijc_136_17 · Cited by 6
A Useful Design Utilizing the Information Fraction in a Group Sequential Clinical Trial With Censored Survival Data
Hsu, C., Chen, C., Hsu, K.-N., & Lu, Y.-H. (2018) · Biometrics · doi:10.1111/biom.12925 · Cited by 6
A Phase II Study of Tailored-dose S-1 Plus Carboplatin Followed by Maintenance S-1 for Advanced Squamous Cell Lung Cancer: OSAKA-LCSG 1102
Yokoi, T., Minami, S., Shiroyama, T., Koba, T., Torii, Y., Sugimoto, H., Niki, M., Mori, M., Morimura, O., Hirashima, T., et al. (2019) · Internal Medicine · doi:10.2169/internalmedicine.1172-18 · Cited by 6
Maintenance Therapy in Metastatic Solid Tumors
Rowinski, E., Fournel, P., Bernichon, E., Bouleftour, W., Magné, N., & Méry, B. (2019) · American Journal of Clinical Oncology · doi:10.1097/coc.0000000000000574 · Cited by 7
Efficacy and safety of first-line pemetrexed plus carboplatin followed by single-agent pemetrexed maintenance in elderly Chinese patients with non-squamous non-small-cell lung cancer
Zhao, X., Yu, H., Zhao, J., Wu, X., Sun, S., Luo, Z., Wang, H., Qiao, J., Chang, J., & Wang, J. (2017) · Oncotarget · doi:10.18632/oncotarget.21186 · Cited by 6
First-line management of metastatic non-small cell lung cancer: An Indian perspective
Ghadyalpatil, N. S., Pandey, A., Krishnamani, I., Srinivas, C., Rafiq, S. J., Hingmire, S., Maturu, V. N., Reddy, R., Kumar, K., Sreekanth, K., et al. (2019) · South Asian Journal of Cancer · doi:10.4103/sajc.sajc_294_18 · Cited by 6
A Phase II Study of Cisplatin Plus Gemcitabine followed by Maintenance Gemcitabine for Advanced Squamous Non-Small-Cell Lung Cancer: Kyoto Thoracic Oncology Research Group 1302
Ikeda, S., Yoshioka, H., Kaneda, T., Yokoyama, T., Niwa, T., Sone, N., Ishida, T., Morita, M., Tomioka, H., Komaki, C., et al. (2019) · Oncology · doi:10.1159/000501967 · Cited by 6
Lung cancer in India: The rewards of REWERDS (REal World Evidence from Retrospective Data analysiS)
Singh, N. (2020) · Current Problems in Cancer · doi:10.1016/j.currproblcancer.2020.100591 · Cited by 6
Randomized phase 2 study comparing irinotecan versus amrubicin as maintenance therapy after first‐line induction therapy for extensive disease small cell lung cancer ( HOT1401 / NJLCG1401 )
Tanaka, H., Hasegawa, Y., Fujita, Y., Nakamura, A., Kikuchi, E., Kawai, Y., Harada, T., Watanabe, N., Yokouchi, H., Usui, K., et al. (2021) · Thoracic Cancer · doi:10.1111/1759-7714.14048 · Cited by 6
Updates in oncology
Sculier, J. P., Meert, A. P., & Berghmans, T. (2014) · European Respiratory Review · doi:10.1183/09059180.00009013 · Cited by 6
Lung cancer Presenting as a Metastasis to the Tibial Bones: A Case Report
Gurrieri, L., Longhi, A., & Braghetti, A. (2015) · Tumori Journal · doi:10.5301/tj.5000200 · Cited by 5
The cost-effectiveness of a NSCLC patient assistance program for pemetrexed maintenance therapy in People's Republic of China
Shi, Q., Hu, S., Furnback, W. E., Guzauskas, G. F., Shen, J., & Wang, B. (2017) · ClinicoEconomics and Outcomes Research · doi:10.2147/ceor.s119818 · Cited by 5
The role of maintenance therapy in the treatment of elderly non-small-cell lung cancer patients: a meta-analysis of randomized controlled trials
Zhang, L., Gao, S., & He, J. (2017) · Drug Design Development and Therapy · doi:10.2147/dddt.s145025 · Cited by 5
PD-L1 expression is a promising predictor of survival in patients with advanced lung adenocarcinoma undergoing pemetrexed maintenance therapy
Qin, Y., Jiang, L., Yu, M., Li, Y., Zhou, X., Wang, Y., Gong, Y., Peng, F., Zhu, J., Liu, Y., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-73013-3 · Cited by 6
Re-examination of Maintenance Therapy in Non-Small Cell Lung Cancer with the Advent of New Anti-cancer Agents
Berge, E. M., & Doebele, R. C. (2013) · Drugs · doi:10.1007/s40265-013-0032-4 · Cited by 5
Adherence to surveillance guidelines in resected NSCLC: Physician compliance and impact on outcomes
Ho, C., Siegfried, J., Remo, K., & Laskin, J. J. (2017) · Lung Cancer · doi:10.1016/j.lungcan.2017.08.012 · Cited by 5
Randomized phase III trial comparing switch-maintenance pemetrexed with observation followed by pemetrexed at progression in advanced NSCLC
Halvorsen, T. O., Stokke, K., Killingberg, K. T., Raj, S. X., Sørhaug, S., Brustugun, O. T., Fløtten, Ø., Helbekkmo, N., Hornslien, K., Madebo, T., et al. (2020) · Acta Oncologica · doi:10.1080/0284186x.2020.1778179 · Cited by 5
Efficacy and safety of anlotinib combined with carboplatin and pemetrexed as first-line induction therapy followed by anlotinib plus pemetrexed as maintenance therapy in EGFR/ALK wild-type advanced non-squamous non-small cell lung cancer in China: a multicenter, single-arm trial
He, Z., Yang, X., Ma, T., Yang, Q., Zhang, C., Chen, Y., Wang, P., D’Incecco, A., Metro, G., Uematsu, S., et al. (2022) · Translational Lung Cancer Research · doi:10.21037/tlcr-22-558 · Cited by 5
Frontline Systemic Therapy With Pemetrexed–Platinum in Nonsquamous Non–Small-Cell Lung Cancer With Asymptomatic Brain Metastases
Alsidawi, S., Chaudhary, R. T., & Karim, N. A. (2014) · American Journal of Therapeutics · doi:10.1097/mjt.0000000000000106 · Cited by 5
Nab-paclitaxel maintenance therapy following carboplatin + nab-paclitaxel combination therapy in chemotherapy naïve patients with advanced non-small cell lung cancer: multicenter, open-label, single-arm phase II trial
Nakao, A., Uchino, J., Igata, F., On, R., Ikeda, T., Yatsugi, H., Hirano, R., Sasaki, T., Tanimura, K., Imabayashi, T., et al. (2018) · Investigational New Drugs · doi:10.1007/s10637-018-0617-6 · Cited by 5
Lungenkarzinom und rheumatoide Arthritis
Rubbert‐Roth, A., Zander, T., Kneitz, C., Baerwald, C., Wirtz, H. R. W., & Witt, C. C. (2016) · Zeitschrift für Rheumatologie · doi:10.1007/s00393-016-0043-0 · Cited by 5
Phase II Trial of Carboplatin and Pemetrexed Plus Bevacizumab with Maintenance Bevacizumab as a First-line Treatment for Advanced Non-squamous Non-small Cell Lung Cancer in Elderly Patients
Takeoka, H., Yamada, K., NAITO, Y., Matsuo, N., Ishii, H., Tokito, T., Azuma, K., Ichiki, M., & Hoshino, T. (2018) · Anticancer Research · doi:10.21873/anticanres.12661 · Cited by 5
Plasma Endoglin is Associated with Favorable Outcome for Pemetrexed-Based Therapy in Advanced Non-Small Cell Lung Cancer
Li, C.-H., Ko, J., Hsiao, Y., Tsai, M.-H., Lai, Y., Hsin, I., Kang, Y., Sheu, G., Lin, W., & Wu, M. (2021) · Cancer Management and Research · doi:10.2147/cmar.s338957 · Cited by 4
Disease control in patients with non‐small cell lung cancer using pemetrexed: Investigating the best treatment strategy
Takahara, Y., Abe, R., Nagae, S., Tanaka, T., Ishige, Y., Shionoya, I., Yamamura, K., Nishiki, K., Nojiri, M., Kato, R., et al. (2024) · Thoracic Cancer · doi:10.1111/1759-7714.15286 · Cited by 4
Quality of Life in Patients with NSCLC Receiving Maintenance Therapy
Rittmeyer, A. (2015) · Cancers · doi:10.3390/cancers7020817 · Cited by 4
Highlights in NSCLC From the 2012 American Society of Clinical Oncology Annual Meeting.
Socinski, M. A. (2012) · PubMed · Cited by 4
Pemetrexed Continuation Maintenance versus Conventional Platinum-Based Doublet Chemotherapy in EGFR-Negative Lung Adenocarcinoma: Retrospective Analysis
Paik, S. S., Hwang, I. K., Park, M. J., & Lee, S. H. (2018) · Tuberculosis & respiratory diseases · doi:10.4046/trd.2017.0090 · Cited by 4
Efficacy and toxicities of combination maintenance therapy in the treatment of advanced non-small-cell lung cancer: an up-to-date meta-analysis
Hu, J., Hu, J., Liu, X., Li, L., & Bai, X. (2019) · Bioscience Reports · doi:10.1042/bsr20182464 · Cited by 4
Heart Failure with Perserved Ejection Fraction Current Diagnostic and Therapeutic Approaches
Shchendrygina, A., Zhbanov, K. A., Privalova, E. V., Yusupova, A. O., Danilogorskaya, Y. A., Salakheeva, E. Y., Sokolova, I. Y., Tsatsurova, S. A., Ageeva, A. A., & Belenkov, Y. N. (2021) · Rational Pharmacotherapy in Cardiology · doi:10.20996/1819-6446-2021-05-01 · Cited by 4
Real-World Treatment Patterns of Lung Cancer in a Resource-Restricted Country: the Experience of Georgia
Kiladze, I., Mariamidze, E., & Jeremic, B. M. (2021) · Health Services Insights · doi:10.1177/11786329211055296 · Cited by 4
Pemetrexed long-term maintenance therapy for advanced severe lung cancer with long-term progression-free survival: a case report
Zhao, W., Zhu, M., Wang, R., & Tong, Z. (2022) · Anti-Cancer Drugs · doi:10.1097/cad.0000000000001402 · Cited by 4
Economic Evaluation of Targeted Therapies for Anaplastic Lymphoma Kinase– and ROS1 Fusion–Positive Non–Small Cell Lung Cancer in India
Gupta, D., Gupta, N. M., Singh, N., & Prinja, S. (2024) · JCO Global Oncology · doi:10.1200/go.23.00260 · Cited by 4
Maintenance therapy following first-line chemotherapy in metastatic colorectal cancer: toxicity and efficacy—single-institution experience
Fedyanin, M., Tryakin, A. A., Vybarava, A., Chekini, D., Покатаев, И. А., Sekhina, O., Гордеев, С. С., Алиев, В. А., & Tjulandin, S. (2014) · Medical Oncology · doi:10.1007/s12032-014-0429-2 · Cited by 4
Pemetrexed Continuation Maintenance in Patients with Nonsquamous Non-small Cell Lung Cancer: Review of Two East Asian Trials in Reference to PARAMOUNT
Yang, J. C., Ahn, M., Nakagawa, K., Tamura, T., Barraclough, H., Enatsu, S., Cheng, R., & Orlando, M. (2014) · Cancer Research and Treatment · doi:10.4143/crt.2013.266 · Cited by 4
The influence of pemetrexed-based continuous maintenance therapy on survival of locally advanced and metastatic lung adenocarcinoma
Huang, Y., Wang, Y., Hu, D., Chen, L., Zhang, R., Cheng, S., Wu, G., & Dong, X. (2019) · Annals of Translational Medicine · doi:10.21037/atm.2019.10.15 · Cited by 4
Efficacy and safety of bevacizumab in advanced lung adenocarcinoma patients with stable disease after two cycles of first‐line chemotherapy: A multicenter prospective cohort study
Ai, B., Zhang, L., Huang, D., Chen, J., Liu, Z., Hu, X., Zhou, S., Hu, Y., Zhao, J., & Yang, F. (2020) · Thoracic Cancer · doi:10.1111/1759-7714.13687 · Cited by 4
Feasibility of cisplatin/pemetrexed with 15 mg/kg bevacizumab for the treatment of patients with advanced non-squamous non-small cell lung cancer
Hirai, F., Seto, T., Inamasu, E., Shimokawa, M., Toyokawa, G., Yoshida, T., Nosaki, K., Takenaka, T., Yamaguchi, M., Takenoyama, M., et al. (2015) · Oncology Letters · doi:10.3892/ol.2015.3086 · Cited by 4

Authors: Paz-Ares, L., de Marinis, F., Dediu, M., Thomas, M., Pujol, J.-L., Bidoli, P., Molinier, O., Sahoo, T. P., Laack, E., Reck, M., Corral, J., Melemed, S., John, W., Chouaki, N., Zimmermann, A. H., Visseren-Grul, C., & Gridelli, C.
Affiliations: Instituto de Biomedicina de Sevilla (ES)
Institutul Oncologic Bucuresti (RO)
Heidelberg University (DE)
Centre Hospitalier Universitaire de Montpellier (FR)
Azienda Ospedaliera San Gerardo (IT)
Centre Hospitalier du Mans (FR)
Jawaharlal Nehru Cancer Hospital and Research Centre (IN)
University Medical Center Hamburg-Eppendorf (DE)
LungenClinic Grosshansdorf (DE)
Eli Lilly (United States) (US)
Azienda Ospedaliera S.Giuseppe Moscati (IT)
Corresponding author: Paz-Ares, Luis
ORCID: Paz-Ares, Luis
Dediu, Mircea
Thomas, Michael
Pujol, Jean-Louis
Molinier, Olivier
Reck, Martin
Gridelli, Cesare
Venue: The Lancet Oncology
Publisher: Elsevier BV
Published: 2012-03
Volume: 13
Issue: 3
Pages: 247-255
ISSN: 1470-2045 (ISSN-L)
DOI: 10.1016/s1470-2045(12)70063-3
OpenAlex: W2005244154
Cited by: 610
References: 33
Citations by year: 2026: 9 · 2025: 9 · 2024: 18 · 2023: 15 · 2022: 23 · 2021: 37 · 2020: 38 · 2019: 40 · 2018: 47 · 2017: 63 · 2016: 44 · 2015: 72 · 2014: 67 · 2013: 80 · 2012: 46
FWCI: 68.37
Type: journal article
Language: en
Open access: green
www.sciencedirect.com
Licence: cc-by-nc-nd
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
www.elsevier.com/legal/tdmrep-license (tdm)
Locations: The Lancet Oncology (publishedVersion)
PubMed (publishedVersion)
BOA (University of Milano-Bicocca) (submittedVersion, cc-by-nc-nd)
Funders: Eli Lilly and Company
Topics: Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Diagnosis and Treatment
Health Sciences › Medicine › Oncology › Lung Cancer Research Studies
Keywords: maintenance therapy, non-squamous non-small cell lung cancer, cisplatin, induction chemotherapy, progression-free survival, best supportive care, disease progression, platinum-based doublets, first-line therapy, ECOG performance status, neutropenia, febrile neutropenia
MeSH terms: Pemetrexed, Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, Carcinoma, Non-Small-Cell Lung, Cisplatin, Double-Blind Method, Drug Administration Schedule, Europe, Female, Glutamates, Guanine, Humans, Lung Neoplasms, Male, Middle Aged, Neoplasm Staging, Placebos, Time Factors, Proportional Hazards Models, Treatment Outcome, Disease-Free Survival, Kaplan-Meier Estimate

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks